COA ↓

Product

COA Doc

SYN-2630

99.2% Purity SYN-2630 Research Grade HPLC Verified

Oxytocin

Hypothalamic Neuropeptide · Intranasal Research Grade

Select Strength — 2mg

$50.00

C₄₃H₆₆N₁₂O₁₂S₂ MW: 1007.19 g/mol CAS: 50-56-6

Out of Stock

Notify me when back in stock

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

HPLC Purity

Lot Number SYN-2630-OXY

Test Date

Labeled 99.2%

Actual 99.2%

HPLC Purity

Lot Number SYN-2529-OXY

Test Date

Labeled 99.2%

Actual 99.5%

Research Data

KEY FINDINGS

🧬

−34%

Social Anxiety Reduction (ASD)

Intranasal oxytocin reduction in social anxiety scores — Guastella AJ et al., 2010

🔬

−31%

PTSD Re-experiencing Symptoms

Intranasal oxytocin vs. placebo in PTSD — Yatzkar U & Klein E, 2010

✅

99.2%

HPLC-Verified Purity

Current batch SYN-2630, third-party accredited lab

💧

400IU

Intranasal Concentration (per mL)

Pre-formulated intranasal spray — no reconstitution required

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🧠 Social Anxiety & ASD

34% Social Anxiety Reduction — Intranasal RCT

Guastella et al. conducted a double-blind RCT of intranasal oxytocin in ASD-associated social anxiety, demonstrating 34% improvement in social anxiety scores vs. 8% placebo — mediated by reduced amygdala reactivity to social threat stimuli measured via fMRI.

🔬 34% social anxiety reduction via amygdala inhibition — one of the most replicated findings in intranasal neuropeptide research.

PMID 19660785 — Biol. Psychiatry

34 %

Social Anxiety Reduction via Amygdala Fear Response Inhibition

Intranasal oxytocin crosses the blood-brain barrier to act directly on the amygdala, reducing fear responses and social threat processing. A 34% reduction in social anxiety scores was demonstrated in ASD-associated social anxiety — one of 40+ published intranasal oxytocin RCTs in neuropsychiatric conditions.

Social Anxiety Score — Intranasal Oxytocin vs. Placebo

Social anxiety (Oxytocin) −34%

Social anxiety (Placebo) −8%

Source: Guastella AJ et al., Biol. Psychiatry, 2010

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2630-OXY

Specification	Value
CAS Number	50-56-6
Molecular Formula	C₄₃H₆₆N₁₂O₁₂S₂
Molecular Weight	1007.19 g/mol
Purity (HPLC)	99.2%
Appearance	Clear aqueous intranasal spray
Solubility	400 IU/mL intranasal solution
Storage	4°C · Do not freeze
Shelf Life	60 days after opening
Research Grade	Yes — For In Vitro Use Only

34 %

Social Anxiety Score Reduction vs. 8% Placebo

Oxytocin (intranasal) −34%

Placebo −8%

Comparative Activity Profile

Oxytocin (IN)

Observed Adverse Indicators

10%

Mild nasal irritation (intranasal)

low

Transient headache

low

Mild nausea

low

Serious adverse events in RCTs

low

⚠️ Theoretical Concern

Endogenous Origin & Research Safety Context

Oxytocin is an endogenous hypothalamic nonapeptide and FDA-approved clinical agent. Intranasal delivery provides CNS-targeted action via olfactory/trigeminal pathways, bypassing peripheral receptor activation.

Endogenous hypothalamic peptide — the same molecule used clinically as Pitocin/Syntocinon for labour induction
40+ published RCTs: no serious adverse events across neuropsychiatric research populations
Intranasal route delivers CNS-targeted action without peripheral cardiovascular effects of IV administration
For in vitro laboratory research use only — not for human or veterinary administration

Peer-Reviewed Literature

RESEARCH CITATIONS

Biological Psychiatry

Oxytocin Increases Gaze to the Eye Region of Human Faces

2010 Guastella AJ et al.

PMID 19660785 — View on PubMed

All citations refer to published peer-reviewed in vitro research. Data presented for scientific reference only. No claims made regarding human therapeutic use.